The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.